Introduction
Memory research is easy to cite and hard to read honestly, and my own work is no exception. Most companies quote a study without telling you who was studied or what the design could support. I ran a twelve-month trial in adults with Alzheimer's disease, and I will walk you through exactly what it measured. This article reports the design, the results, the limits, and the follow-up analyses in plain language. It also separates what that trial established from what it could not, a line that marketing blurs constantly. You will finish able to judge my research the way I would judge anyone else's.
What Memory Research Can Support, and What It Cannot
Study design decides what memory research is worth, and nothing else comes close in importance. A randomized trial with a placebo group can support a causal reading when it is large enough and long enough. An open-label trial without a placebo group cannot, whatever its results look like. Knowing that distinction protects you from most of the marketing in this industry, mine included.
Placebo effects are real and they are measurable in cognitive testing. Participants who know they are receiving something often perform differently, and caregivers who know often rate differently. Practice effects compound the problem, since taking the same test repeatedly improves scores on its own. Any single-arm study carries both of those influences inside its results.
Federal law draws the other boundary, and I respect it fully. No dietary supplement treats, cures, mitigates, manages, or prevents any disease, and mine is no exception. Supplements supply nutrients that support normal cellular structure and function within a healthy lifestyle. My memory research examines how the body uses those raw materials, not whether a product addresses a diagnosis.
Why Memory-Related Research Draws So Much Attention
Scale explains the attention memory research receives. Roughly one in nine Americans aged 65 and older now lives with Alzheimer's dementia, some 7.4 million people in 2026 (Alzheimer's Association, 2026). Unpaid family caregiving accounts for most of the labor behind that figure. What drives memory change in the first place is covered in what causes memory loss.
Single-arm studies still reach publication, and they serve a purpose worth naming. An early study shows whether an intervention is tolerated and whether the measures behave as expected. Funding a placebo-controlled trial afterward requires financial and other resources most supplement companies never commit. Saying that plainly is more useful to you than pretending my trial settled anything.
Demand of that size attracts serious science and careless marketing in equal measure. Parkinson's disease and multiple sclerosis draw the same mixture for the same reasons. Anyone facing a diagnosis of that kind belongs under the care of a physician who knows the full history. Nothing I publish substitutes for that relationship, and nothing I sell does either.
What We Measured in Our Twelve-Month Clinical Trial
My colleagues and I conducted a twelve-month, open-label trial without a placebo group (Lewis et al., 2013). We enrolled 34 adults with moderate to severe Alzheimer's disease, and 26 of them completed the study. Participants averaged 79.9 years of age, and 82 percent were women. Every participant had carried the diagnosis for at least one year before enrolling.
Each participant took one teaspoon of an aloe polymannose multinutrient complex four times daily. We assessed cognition at baseline and every three months using the ADAS-cog, the Mini-Mental State Examination, and two other instruments. Blood was drawn at baseline and at twelve months for cytokines, growth factors, and cell-surface markers. That panel let us examine cognitive function research questions and immune measures in the same adults rather than in separate studies.
What a formula contains matters as much as what a trial measures. The complex was built around aloe polysaccharides, which are long chains of sugar molecules studied for their effects on cell signaling. What those molecules are, and what researchers have measured about them, is explained in aloe polysaccharides. Whether one ingredient or a combination serves a given purpose is a separate question taken up in single vs multi-ingredient supplements.
What the Results Showed, and What They Did Not
The ADAS-cog score improved significantly at nine and twelve months in those adults with Alzheimer's disease (Lewis et al., 2013). The ADAS-cog is the gold standard for assessing cognition, and 46 percent of those adults showed a clinically meaningful change. Several cognitive measures correlated with cytokine levels in the same participants at twelve months. We also tracked brain-derived neurotrophic factor, a protein supporting neuron growth, alongside cognition in that trial (Martin et al., 2017). A later analysis of the same adults reported that an elevated Th1/Th2 cytokine ratio moved downward over the twelve months (Lewis et al., 2023). Several of those shifts correlated with improved cognition in those adults. CD14+ monocytes rose from 10.3 percent at baseline to 39.8 percent at twelve months in those adults (Lewis et al., 2013).
The limits belong beside the findings rather than after them. Twenty-six completers in a single-arm study cannot establish that any supplement addresses Alzheimer's disease. Cognitive improvement in an open-label design may reflect the supplement, the attention, the practice effect, or all three. What the trial does establish is that these outcomes were measured, reported, and published for others to examine.
Published human research on a finished formula remains uncommon in this category. Most supplement companies cite studies of raw materials tested in cell culture or in rodents. My colleagues and I also ran a double-blind, randomized trial of other dietary supplements in healthy older adults (Lewis et al., 2014). That study measured cognitive and immune outcomes in those healthy adults with significant, yet not overly impressive, findings. Naming the design honestly is what makes any of this worth citing.
How Our Memory Research Fits the Wider Literature
Our memory research sits inside a literature with a mixed record, and pretending otherwise would be dishonest. Dementia incidence was no lower with Ginkgo biloba than with placebo among 3,069 adults aged 75 and older (DeKosky et al., 2008). Memory scores favored a daily multivitamin over placebo across three years in 3,562 older adults (Yeung et al., 2023). Those two results, from trials far larger than mine, show how uneven this field is.
My colleagues and I later reviewed twenty-one nutrients and phytonutrients for their effects on cognition (Lewis et al., 2021). A narrative review of that kind maps what has been studied, and it does not rank products. I will not stretch it into a comparison it was never designed to make. How the major ingredients grade against their own trial evidence is set out in best supplements for memory loss.
Inflammation is correlated with much of this literature, which is why our cytokine measures mattered to us. Immune signaling and memory are connected through pathways described in inflammation and brain health. Reading that mechanism helps explain why we measured blood markers alongside cognitive tests. It also explains why I keep publishing rather than simply advertising.
How I Use This Memory Research in My Own Decisions
My own habits came first, and the research came second. I have eaten whole plant foods since 1999, and I have trained drug-free as a bodybuilder for decades. I sleep on a fixed schedule and I keep my alcohol intake at zero. No supplement I have studied competes with those habits for effect size.
I take Daily Brain Care daily as one part of that routine. The formula carries aloe polysaccharides, stabilized rice bran, golden flaxseed, wild yam root, tart cherry, N-acetyl cysteine, and inositol hexaphosphate, among other ingredients. Each ingredient earned its place through published science rather than through popularity. My full academic and research record is available on my About page.
Two sentences would be easy to write here, and I refuse each one. Calling my trial proof that a supplement addresses Alzheimer's disease would misrepresent an open-label design. Calling my formula superior to another product would require head-to-head trials nobody has run.
Conclusion
Memory research deserves careful reading, and that standard applies to the research behind products I sell. Our twelve-month trial measured cognition and immune function in adults with Alzheimer's disease and reported improvement in cognitive scores. Its open-label design cannot establish that any supplement addresses a disease, and I claim nothing of the sort. What I can tell you is that the formula was studied, published, and described honestly. Read the trial, weigh the limits, and then decide whether Daily Brain Care belongs in your routine.
Frequently Asked Questions
What is memory research?
Memory research covers laboratory work, observational studies, and clinical trials examining how memory changes and what influences it. Design determines what each study can support. An open-label trial without a placebo group describes what was observed rather than what caused it.
What did your memory-related research measure?
We measured cognition every three months and immune markers twice in 34 adults with moderate to severe Alzheimer's disease (Lewis et al., 2013). Twenty-six of those adults completed the twelve months. Cognitive scores improved significantly at nine and twelve months in those adults.
Does the research prove the supplement works for Alzheimer's disease?
No, and I make no such claim. An open-label trial without a placebo group in 26 completers cannot establish that any dietary supplement addresses a disease. Supplements support normal structure and function within a healthy lifestyle.
How much did participants take in the trial?
Each participant took one teaspoon of the aloe polymannose multinutrient complex four times daily for twelve months (Lewis et al., 2013). Serving sizes on a retail label are not the same measure as a study dose, and I describe them separately.
References
Alzheimer's Association. (2026). 2026 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 22. https://doi.org/10.1002/alz.71345
DeKosky, S. T., Williamson, J. D., Fitzpatrick, A. L., Kronmal, R. A., Ives, D. G., Saxton, J. A., Lopez, O. L., Burke, G., Carlson, M. C., Fried, L. P., Kuller, L. H., Robbins, J. A., Tracy, R. P., Woolard, N. F., Dunn, L., Snitz, B. E., Nahin, R. L., & Furberg, C. D. (2008). Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA, 300(19), 2253–2262. https://doi.org/10.1001/jama.2008.683
Lewis, J. E., McDaniel, H. R., Agronin, M. E., Loewenstein, D. A., Riveros, J., Mestre, R., Martinez, M., Colina, N., Abreu, D., Konefal, J., Woolger, J. M., & Ali, K. H. (2013). The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer's disease. Journal of Alzheimer's Disease, 33(2), 393–406. https://doi.org/10.3233/JAD-2012-121381
Lewis, J. E., Melillo, A. B., Tiozzo, E., Chen, L., Leonard, S., Howell, M., Diaz, J., Gonzalez, K., Woolger, J. M., Konefal, J., Paterson, E., & Barnes, D. (2014). A double-blind, randomized clinical trial of dietary supplementation on cognitive and immune functioning in healthy older adults. BMC Complementary and Alternative Medicine, 14, 43. https://doi.org/10.1186/1472-6882-14-43
Lewis, J. E., Poles, J., Shaw, D. P., Karhu, E., Khan, S. A., Lyons, A. E., Sacco, S. B., & McDaniel, H. R. (2021). The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. Journal of Clinical and Translational Research, 7(4), 575–620. https://pubmed.ncbi.nlm.nih.gov/34541370/
Lewis, J. E., McDaniel, H. R., Woolger, J. M., & Khan, S. A. (2023). The characterization of the Th1/Th2 ratio in moderate-severe Alzheimer's disease patients and its response to an aloe polymannose-based dietary supplement. Journal of Alzheimer's Disease, 96(4), 1723–1737. https://doi.org/10.3233/JAD-230659
Martin, A., Stillman, J., Miguez, M.-J., McDaniel, H. R., Konefal, J., Woolger, J. M., & Lewis, J. E. (2017). The effect of dietary supplementation on brain-derived neurotrophic factor and cognitive functioning in Alzheimer's dementia. Journal of Clinical and Translational Research, 3(3), 337–343. https://doi.org/10.18053/jctres.03.201703.006
Yeung, L. K., Alschuler, D. M., Wall, M., Luttmann-Gibson, H., Copeland, T., Hale, C., Sloan, R. P., Sesso, H. D., Manson, J. E., & Brickman, A. M. (2023). Multivitamin supplementation improves memory in older adults: A randomized clinical trial. American Journal of Clinical Nutrition, 118(1), 273–282. https://doi.org/10.1016/j.ajcnut.2023.05.011
